Couta - I like to see differing viewpoints on a thread - you can always disagree with their thoughts but often there is a kernel of truth there as well. This company does seem to be a faith stock - you either believe or you don't! I don't hold but am following. It sort of reminds me WDT unfortunately...regards!
I'm all for differing viewpoints but once one has made their point/s then things should be dropped, personally I don't believe non holders should take control of a thread and sabotage it to the point where holders can't be bothered posting anymore primarily because they have become too weary to be bothered due to the constant negative rehashing going on over and over again anyway nuff said.
lol......so PEB signed up an exclusive JV partner 4 years ago that was not even interested in it products for at least another 4 years.
...
This from PEB in the May 2011 announcement about Spain.....
ORYZON TO MARKET PACIFIC EDGE NOVEL DIAGNOSTIC Cxbladder IN SPAIN & PORTUGAL
Pacific Edge Limited and Spanish company Oryzon S.A (Oryzon) have signed an
exclusive license agreement to market Pacific Edge''s (PE) novel diagnostic
test for the detection of bladder cancer, Cxbladder in Spain and Portugal.
Under the terms of the agreement, Oryzon will market and offer laboratory
services to urologists and general practitioners (GP) for the detection of Bladder cancer using CXbladder in Spain and Portugal.
Yes Snaps, I agree PEB could have some explaining to do there, although as one who has run or helped to run businesses in a fast-moving sector (not this one) I'm very aware that things outside one's control often happen unexpectedly. It was hard enough keeping board members in the loop, let alone shareholders. And I was a member of the Institute of Directors, with profound respect for the fiduciary duty owed to shareholders I was serving, who included a venture capital investor.
But listening to DD in his presentation last week I recalled what it was like, juggling numerous balls in the air as head of a not-large company and having to be able to modify strategy very fast - something NZ companies are reputedly good at. I thought DD did an excellent job addressing issues over a wide range. Okay, PEB have stuffed up on a couple of issues, but that happens. And we can always attack him for beginning every answer with "Yes that's a very good question". His PR advisers probably told him to do that, and does it matter?.
But from his presentation overall I was satisfied things are broadly on track (even though the track ahead is never clear) and I'll be taking up the capital raising offer.
Another thing not all shareholders may appreciate is the complexity of the cancer diagnostics and treatment business. As one who has recently had cancer experience and been using Google to keep up with the specialists treating me, I'm very aware that approvals of new treatments don't happen as fast as we'd like. But that's to be expected. The medical bureaucracy has a tough job keeping up, especially when approving the expenditure of public money.
The number of new treatments and diagnostic tools now becoming available globally is mind-blowing. And while there is room for many of them to be adopted to a limited extent, far fewer will stand out and become the standard treatments based on efficacy and price. Not based on how hard they are promoted by big Pharma. The specialists (and medical bureaucrats) know that big Pharma is less interested in curing patients than in keeping them under longterm expensive treatment. So I disagree with those who say PEB would de better by being taken captive by big Pharma.
It's a complex environment, and I think the CxBladder strategy is admirably constructed to achieve success.
How their results stack up against CxBladder Predict, Triage etc and the fact that they are well behind PEB's timeline and the so-called obstacles ahead will be immaterial.
What they have going for them is they are a yankee outfit. This in itself will be enough to make a big public fan-fared splash into the bladder cancer market. PEB's sign up with the CMS, VA and KP will be made to "mark time" until after OncoCyte have got themselves operating in the market. The US will then announce to the world how they are the leaders in this market of cutting edge technology & science and their population will all say "WOW, we are the world leaders in this as well...." They won't care about being labelled "Johnny come lately's" either.
No, not a hater of the US - just cynical about how they go about things (not just in medicine either !!).
If only we had ditched DD & CS a couple of years ago and replaced them with Balance and Skid, we would all be in the land of milk and honey now.
I was just after some stats from some of the posters who know alot about the science to see how they compare. I think its good to know your competition.
In my opinion there are to many who either accept of reject without asking questions that may help to understand the market
Trolls aren't after answers its all about self amusement for them and trying to discourage as many current holders as possible by controlling the thread ( Notice how the word controlling also contains a Troll)
I beg to differ--How else can you get answers than by asking question--Perhaps thinking rightly or wrongly about things that no one has considered much up to now.
Maybe even venturing to try and think of possible solutions.
But I havent seen much evidence of anyone else trying to do the same or considering what has been brought up.
Not sure if talk of trolls is really going to achieve much.
If your after real answers you have got to start somewhere
Yes Snaps, I agree PEB could have some explaining to do there, although as one who has run or helped to run businesses in a fast-moving sector (not this one) I'm very aware that things outside one's control often happen unexpectedly. It was hard enough keeping board members in the loop, let alone shareholders. And I was a member of the Institute of Directors, with profound respect for the fiduciary duty owed to shareholders I was serving, who included a venture capital investor.
But listening to DD in his presentation last week I recalled what it was like, juggling numerous balls in the air as head of a not-large company and having to be able to modify strategy very fast - something NZ companies are reputedly good at. I thought DD did an excellent job addressing issues over a wide range. Okay, PEB have stuffed up on a couple of issues, but that happens. And we can always attack him for beginning every answer with "Yes that's a very good question". His PR advisers probably told him to do that, and does it matter?.
But from his presentation overall I was satisfied things are broadly on track (even though the track ahead is never clear) and I'll be taking up the capital raising offer.
Another thing not all shareholders may appreciate is the complexity of the cancer diagnostics and treatment business. As one who has recently had cancer experience and been using Google to keep up with the specialists treating me, I'm very aware that approvals of new treatments don't happen as fast as we'd like. But that's to be expected. The medical bureaucracy has a tough job keeping up, especially when approving the expenditure of public money.
The number of new treatments and diagnostic tools now becoming available globally is mind-blowing. And while there is room for many of them to be adopted to a limited extent, far fewer will stand out and become the standard treatments based on efficacy and price. Not based on how hard they are promoted by big Pharma. The specialists (and medical bureaucrats) know that big Pharma is less interested in curing patients than in keeping them under longterm expensive treatment. So I disagree with those who say PEB would de better by being taken captive by big Pharma.
It's a complex environment, and I think the CxBladder strategy is admirably constructed to achieve success.
Big Pharma is a very emotive word --There are some bad apples alright but there are also alot of lifesaving contributions they have made--It really depends on the company--Just at first glance Genomics seems ok ,and Im sure there are lots of others that probably contributed to your cure(hopefully)
In terms of a partnership,the economics makes sense.
I was just after some stats from some of the posters who know a lot about the science to see how they compare. I think its good to know your competition.
In my opinion there are to many who either accept of reject without asking questions that may help to understand the market
Yep - we tend to be split between the gullible and cynical. With this type of product it is always going to be hard to do any form of DD on market so you are more reliant on the company than normal. Which I believe puts greater onus on them to be responsible.
As far as I can read - no date for cash positive, no date for profitability just the glib - on our way to $100m.
If they triple sales each year it will take at least 4 1/2 years to get to that figure - which I would have no problem with. Great achievement. Will it be profitable? If so how profitable? Needs to be making around $18m+ pre tax to justify current share price (on say a PE 15) and over those 4 years - will cash burn go up until profitable? Current burn would see them need another $40m in funding. That has to seriously dilute share value as its pretty hard to put a more positive spin on things than the current one.
Looks like SP has a lot further to fall in near term.
Originally Posted by Crackity
Reply With Quote
Bookmarks